These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8141637)

  • 61. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.
    Am J Kidney Dis; 2001 Jan; 37(1 Suppl 1):S182-238. PubMed ID: 11229970
    [No Abstract]   [Full Text] [Related]  

  • 62. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
    Bieber E
    J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Epoetin alfa--focus on nutritional therapy. Case study of the anemic patient.
    College J
    ANNA J; 1996 Aug; 23(4):416-9. PubMed ID: 8900689
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Erythropoietin 1991--an overview.
    Eschbach JW
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):3-9. PubMed ID: 1928076
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
    Johnson CA; Rosowski E; Zimmerman SW
    Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Time to consider the role of epoetin.
    Zhang Y; Thamer M
    Kidney Int; 2006 May; 69(10):1917; author reply 1917-8. PubMed ID: 16688199
    [No Abstract]   [Full Text] [Related]  

  • 68. Epoetin alfa: patient management issues and development through recombinant DNA technology. Part 1: Focus on Epoetin alfa patient management and recombinant DNA technology.
    Latham D; Nichols E
    ANNA J; 1990 Aug; 17(4):311-4. PubMed ID: 2396857
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Administration of Epoetin alfa. Case study of the anemic patient.
    Cutler M
    ANNA J; 1997 Aug; 24(4):459-65; quiz 466. PubMed ID: 9325701
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transfusion therapy: associated risks and alternative approaches.
    Picard VT; Sayers MH; Spinowitz BS; Richner RE
    ANNA J; 1990 Dec; 17(6):457-64. PubMed ID: 2256728
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epoetin alfa--focus on nursing case management. Case study of the anemic patient.
    White RB
    ANNA J; 1996 Jun; 23(3):326-9. PubMed ID: 8716992
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessing the impact of concomitant therapies on anemia in dialysis patients. Case study of the anemic patient.
    Gregory N
    Nephrol Nurs J; 2000 Jun; 27(3):320-3; quiz 324-5. PubMed ID: 11249331
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Categorizing the response to Epoetin alfa therapy. Case study of the anemic patient.
    Watson C
    ANNA J; 1999 Dec; 26(6):629-32. PubMed ID: 10876477
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tools for analyzing trends in anemia management case study of the anemic patient.
    Aiello J
    Nephrol Nurs J; 2000 Feb; 27(1):57-60. PubMed ID: 10852692
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Management of the chronic renal failure patient receiving epoetin alfa for the treatment of anemia.
    Binkley LS
    Transplant Proc; 1991 Apr; 23(2):1831-2. PubMed ID: 2053169
    [No Abstract]   [Full Text] [Related]  

  • 77. Perspectives on the improvement of quality of life with epoetin alfa therapy.
    Lundin AP; Delano BG; Quinn-Cefaro R
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):22S-26S. PubMed ID: 2345708
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Case management of the anemic patient. Epoetin alfa: focus on dialysis efficiency.
    Latham D; Geisman J
    ANNA J; 1991 Dec; 18(6):588-9. PubMed ID: 1750793
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.